Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00424437 · ClinicalTrials.gov registry record · Phase 3

Six Month Clinical Trial Assessing Efficacy And Safety Of Inhaled Insulin In Type 1 Diabetes Mellitus.

A Phase 3 study, sponsored by Pfizer.

Completed
Registry status
Phase 3
Development phase
320
Enrollment target

NCT00424437 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 320 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00424437, a Phase 3 study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 3
Development phase
320 participants
Enrollment target

Study Summary

To determine, in subjects with Type 1 Diabetes Mellitus: 1. Whether glycemic control can be achieved at least as effectively with an insulin regimen involving pre-meal inhaled insulin plus a single bedtime Ultralente injection as with a conventional subcutaneous insulin regimen involving 2-3 mixed Regular/NPH insulin injections per day. 2. The toleration and safety of inhaled insulin therapy and its effects after 6 months, if any, on measures of pulmonary function.

Interventions

  • DRUG Inhaled human insulin

Trial Details

FieldValue
Enrollment Target 320 participants
Start Date 1999-09
Est. Completion 2000-09
Phase Phase 3

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT00424437

The ClinicalTrials.gov registry entry for NCT00424437 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Inhaled human insulin is the first listed.

NCT00424437 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00424437 about?

NCT00424437 is a clinical study titled "Six Month Clinical Trial Assessing Efficacy And Safety Of Inhaled Insulin In Type 1 Diabetes Mellitus.". To determine, in subjects with Type 1 Diabetes Mellitus: 1. Whether glycemic control can be achieved at least as effectively with an insulin regimen involving pre-meal inhaled insulin plus a single bedtime Ultralente injection as with a conventional subcutaneous insulin regimen involving 2-3 mixed ...

What is the current status of trial NCT00424437?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 320 participants. The study started on 1999-09. Estimated completion is 2000-09.

What interventions are being tested in trial NCT00424437?

The interventions under investigation include: Inhaled human insulin (DRUG).

Who is sponsoring clinical trial NCT00424437?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.